CompanyGraph
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
600771 · SSE · China
guangyuyuan.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleLevered free cash flow is $34M, above the global median of $18.73M
- FinancialsAltman Z-Score 6.08: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.83BCNY1.02B · vs all stocks (USD)
Trailing P/E
99.71xRevenue (TTM)
1.41BCNY211.21M · vs all stocks (USD)
Profit Margin
5.01%Beta
0.2830xvs all stocks
52-Week Change
-26.41%vs all stocks
Market Capitalization
6.83BCNY1.02B · vs all stocks (USD)
Enterprise Value
6.37BCNY950.88M · vs all stocks (USD)
Trailing P/E
99.71xForward P/E
8.26xPrice to Sales (TTM)
4.83xPrice to Book (MRQ)
4.10xEnterprise to Revenue
4.50xEnterprise to EBITDA
44.54xGross Margin
67.89%Profit Margin
5.01%Operating Margin
0.60%Return on Assets (TTM)
2.74%Return on Equity (TTM)
4.33%Revenue (TTM)
1.41BCNY211.21M · vs all stocks (USD)
Revenue per Share (TTM)
2.86CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-7.20%Gross Profit (TTM)
938.63MCNY140.16M · vs all stocks (USD)
EBITDA (TTM)
178.31MCNY26.63M · vs all stocks (USD)
Net Income (TTM)
70.84MCNY10.58M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
35.00%Operating Cash Flow (TTM)
233.69MCNY34.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
227.67MCNY34.00M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
20.35MCNYFY2025 · Dec 31, 2025Revenue
1.37BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
443.70MCNYFY2025 · Dec 31, 2025Gross Profit
925.60MCNYFY2025 · Dec 31, 2025Operating Income
138.89MCNY20.74M · vs all stocks (USD)
Pre-tax Income
103.04MCNYFY2025 · Dec 31, 2025Income Tax Expense
39.35MCNYFY2025 · Dec 31, 2025Net Income
63.69MCNYFY2025 · Dec 31, 2025EBIT
105.56MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
178.31MCNYFY2025 · Dec 31, 2025Research & Development
38.47MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
542.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
32.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.52MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
484.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
484.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
63.69MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-646.07KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-3.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-9.81MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
296.73MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
63.69MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.15MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-82.05MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.65MCNYFY2025 · Dec 31, 2025Capital Expenditures
-6.24MCNYFY2025 · Dec 31, 2025Purchase of Investments
-600.00KCNYFY2025 · Dec 31, 2025Sale of Investments
468.65KCNYFY2025 · Dec 31, 2025Other Investing Activity
-10.18MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-16.55MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-8.14MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.19MCNYFY2025 · Dec 31, 2025Other Financing Charges
9.33MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
370.00CNYFY2025 · Dec 31, 2025Shares Outstanding
489.49MSharesUpdated Sep 22, 2026Float Shares
316.98MSharesUpdated Sep 22, 2026% Held by Insiders
21.12%vs all stocks
% Held by Institutions
1.98%vs all stocks
Total Cash (MRQ)
538.46MCNY80.41M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.10CNYUpdated Sep 22, 2026Total Debt (MRQ)
53.32MCNY7.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0316xCurrent Ratio (MRQ)
2.14xBook Value per Share (MRQ)
3.41CNYUpdated Sep 22, 2026Total Assets
2.44BCNY363.88M · vs all stocks (USD)
Total Current Assets
1.58BCNYFY2025 · Dec 31, 2025Total Liabilities
783.77MCNYFY2025 · Dec 31, 2025Total Non-current Assets
853.19MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
47.31MCNYFY2025 · Dec 31, 2025Total Current Liabilities
736.46MCNYFY2025 · Dec 31, 2025Cash
285.29MCNYFY2025 · Dec 31, 2025Cash Equivalents
11.46MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
296.75MCNYFY2025 · Dec 31, 2025Accounts Receivable
269.60MCNYFY2025 · Dec 31, 2025Inventory
749.98MCNYFY2025 · Dec 31, 2025Accounts Payable
107.57MCNYFY2025 · Dec 31, 2025Short-term Debt
21.10MCNYFY2025 · Dec 31, 2025Other Current Liabilities
26.45MCNYFY2025 · Dec 31, 2025Long-term Debt
25.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
489.49MCNYFY2025 · Dec 31, 2025Retained Earnings
-471.18MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.65BCNY246.84M · vs all stocks (USD)
52-Week Low
12.45CNYUpdated Sep 22, 202652-Week High
20.40CNYUpdated Sep 22, 202652-Week Change
-26.41%vs all stocks
Beta
0.2830xvs all stocks
50-Day MA
14.15CNYUpdated Sep 22, 2026200-Day MA
16.03CNYUpdated Sep 22, 2026Avg 10-Day Volume
6.10MSharesUpdated Sep 22, 2026Avg 30-Day Volume
7.64MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.1400CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.68Profit Margin: 0.05
Financial Health
Altman Z-Score 6.08: safe zoneNotable
Altman Z-Score: 6.08
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Levered free cash flow is $34M, above the global median of $18.73MNotable
Levered free cash flow (USD): 33,997,356.612Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MoonLake Immunotherapeutics
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk